Trials / Completed
CompletedNCT00284050
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab 0.3 mg | 6 mg/ml ranibizumab solution for intravitreal injection |
| DRUG | Ranibizumab 0.5 mg | 10 mg/ml ranibizumab solution for intravitreal injection |
| DRUG | Sham injection | Non-treatment control for sham intravitreal injection. |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-01-31
- Last updated
- 2011-02-24
- Results posted
- 2011-01-20
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00284050. Inclusion in this directory is not an endorsement.